Use of SGLT2 inhibitors was associated with a significantly lower risk of major cardiac events and mortality in patients with T2DM and coronary ischemia, according to findings published in the Diabetes & Metabolism Journal.

The retrospective analysis included 671 patients who underwent coronary angiography and fractional flow reserve assessment between 2014 and 2016. Among them, 206 patients (30.7%) received SGLT2 inhibitors, while 484 (72.1%) achieved complete revascularization (CR). During a mean follow-up of 36 months, 100 MACE and 89 deaths were recorded.

SGLT2 inhibitor users experienced lower rates of MACE (8.3% vs. 17.8%, P = 0.002) and all-cause mortality (6.3% vs. 16.3%, P < 0.001) compared with non-users. Multivariable Cox regression confirmed that SGLT2 inhibitors were associated with reduced MACE risk in both CR and incomplete revascularization groups (hazard ratio [HR] 0.498; 95% confidence interval [CI] 0.246–0.938; and HR 0.341; 95% CI 0.123–0.805, respectively).

These results highlight consistent reductions in cardiac events and mortality with SGLT2 inhibitors, independent of revascularization status.